A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518276-32-00

Acronym

90301900NSC2001

Enrollment

Registered

2025-03-10

Start date

2025-08-29

Completion date

Unknown

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced and unresectable Stage III non-small cell lung cancer

Brief summary

ORR using Independent Central Review (ICR) assessments according to RECIST v1.1 (best response)

Interventions

DRUGJNJ-90301900

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ORR using Independent Central Review (ICR) assessments according to RECIST v1.1 (best response)	—

Countries

France, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026